This study was therefore undertaken to further explore the potential value of PET imaging with 18F-Florzolotau on a large cohort of patients with PSP across different phenotypes, and to investigate whether this imaging biomarker may capture the distribution patterns and regional vulnerability of tau pathology in PSP. The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.